In this episode, we speak with Björn Schimmöller, Co-Founder and CEO of iuvantium, a synthetic immunobiology company developing new modalities for the next generation of immunotherapies.
The founding journey of iuvantium from Oxford University.
How Iuvantium is enhancing immune system efficiency and reducing clinical trial uncertainty using inorganic chemistry.
‘Decoding’ the immune system and how personalised medicine may lead to the next leaps in immunotherapy.
Antiverse is an artificial intelligence-driven techbio company that specialises in antibody design against difficult-to-drug targets, including G-protein coupled receptors (GPCRs) and ion channels. Headquartered in Cardiff, UK and with offices in Boston, MA, Antiverse combines state-of-the-art machine learning techniques and advanced cell line engineering to develop de novo antibody therapeutics. With a primary focus on establishing long-term partnerships, Antiverse has collaborated with two top 20 global pharmaceutical companies. In addition, they are developing a strong internal pipeline of antibodies against several challenging drug targets across various indications.
We'll notify you when a new event is scheduled. Fill out this form to sign up for marketing communications from Antiverse. We post about upcoming events on LinkedIn and Twitter.
Podden och tillhörande omslagsbild på den här sidan tillhör
Murat Tunaboylu. Innehållet i podden är skapat av Murat Tunaboylu och inte av,
eller tillsammans med, Poddtoppen.